Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2023, with a specific reporting date of February 14, 2023. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details equity compensation transactions.
| Executive | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Ms E Walmsley | Chief Executive Officer | Ordinary Shares | 125,482 | £15.010 |
| Mr I Mackay | Chief Financial Officer | Ordinary Shares | 77,751 | £15.010 |
| Ms D Conrad | Chief People Officer | Ordinary Shares | 22,842 | £15.010 |
| Mr J Ford | SVP and Group General Counsel | Ordinary Shares | 22,223 | £15.010 |
| Ms S Jackson | SVP, Global Communications | Ordinary Shares | 13,830 | £15.010 |
| Mr L Miels | Chief Commercial Officer | Ordinary Shares | 53,528 | £15.010 |
| Ms S Ramakrishnan | Chief Digital and Technology Officer | ADSs | 11,145 | $36.320 |
| Mr D Redfern | President Corporate Development | Ordinary Shares | 30,942 | £15.010 |
| Mr R Simard | President, Global Supply Chain | Ordinary Shares | 24,852 | £15.010 |
| Mr P Thomson | President, Global Affairs | Ordinary Shares | 16,260 | £15.010 |
| Ms D Waterhouse | CEO, ViiV Healthcare | Ordinary Shares | 39,600 | £15.010 |
| Dr T Wood | Chief Scientific Officer | Ordinary Shares | 18,792 | £15.010 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents the routine granting of deferred bonus awards on February 9, 2023, in accordance with the shareholder-approved Remuneration Policy.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that Executive Directors are required to defer 50% of the bonus equivalent of the first 200% of salary, with excess deferred in full. Other Leadership Team members defer 25% of the bonus equivalent of the first 170% of salary. Awards are granted as restricted awards over ADSs for US participants and nil-cost options over Ordinary Shares for others.
Key Facts for Investor Verification
- Transaction Date: All awards were granted on February 9, 2023.
- Valuation Basis: Ordinary Shares were valued at £15.010; ADSs were valued at $36.320.
- Deferral Terms: Awards are subject to a three-year deferral period with dividend reinvestment accruing during this time.
- Instrument Type: Most awards are Ordinary Shares; one award (Ms S Ramakrishnan) is in ADSs.
- Compliance: Transactions comply with the GlaxoSmithKline 2017 Deferred Annual Bonus Plan approved by shareholders in 2017.